TD Cowen Reiterates Buy Rating on Alkermes plc (ALKS)
TD Cowen maintains its buy rating for Alkermes plc with a price target of $50, a 2.09% downside from the current price.
Key Points
- TD Cowen reiterated its buy rating on Alkermes plc (ALKS) with a $50 price target on June 22, 2026.
- TD Cowen's $50 price target implies 2.09% downside from Alkermes plc's ($ALKS) current $51.06 share price.
- Shares of Alkermes traded near $44.99 on Monday, with a market cap of about $7.5 billion and a P/E ratio of 50.
- Vanguard Portfolio Management LLC opened a new position with 9,511,112 shares valued at approximately $336.3 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
TD Cowen reiterated its buy rating on Alkermes plc (NasdaqGS: ALKS) on June 22, 2026, maintaining a price target of $50. This move signals continued confidence in the biopharmaceutical company's prospects. Shares of Alkermes traded near $44.99 on Monday.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in TD Cowen's Alkermes plc Position
TD Cowen's analyst Joseph Thome reiterated the buy rating for Alkermes plc, setting a target price of $50. This reaffirmation suggests that the firm expects the stock to outperform based on its current valuation and growth prospects.
Other Institutional Activity in Alkermes plc
Vanguard Portfolio Management LLC opened a new position in Alkermes, acquiring 9,511,112 shares valued at about $336.3 million. Meanwhile, BlackRock, Inc. increased its holdings slightly by 41,998 shares, bringing its total to 28,314,410 shares worth approximately $1 billion. Baker Bros. Advisors LP maintained its stake at 10,012,267 shares, valued at $354 million. State Street Corp trimmed its position by 7,572 shares, ending with 9,465,286 shares valued at around $334.7 million. Renaissance Technologies LLC reduced its stake by 507,600 shares, holding 6,160,428 shares worth about $217.8 million.
Alkermes plc Stock Up 7.7%
Shares of Alkermes plc traded near $44.99 on Monday. The company has a market capitalization of approximately $7.5 billion, with a P/E ratio of 50 and a forward P/E of about 28.9. Alkermes has a beta of 0.334, indicating lower volatility than the market. The stock's 52-week range is between $25.17 and $45.76, with a 50-day moving average of $37.84 and a 200-day moving average of $32.18. Alkermes has a current ratio of 2.27 and a quick ratio of 1.53, with a debt-to-equity ratio of 90.30.
$ALKS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Alkermes reported revenue of approximately $1.56 billion, reflecting a growth rate of 28.2%. The company's net margin stands at 9.8%, with a return on equity of 9.36%. Earnings per share (EPS) were $0.90. The next earnings report is scheduled for July 28, 2026.
Insider Buying and Selling at Alkermes plc
Recent insider transactions at Alkermes plc include planned sales by Wright Christopher and David Joseph Gaffin. EVP R&D and Chief Medical Officer Craig Hopkinson sold 9,000 shares at an average price of $41.67 on June 1, 2026, under a planned sale. He also bought 5,000 shares on the same day at $19.34, which was not planned. Samuel Joseph Parisi, VP of Finance, sold 16,217 shares on May 29, 2026.
Analysts Set New Price Targets
TD Cowen maintained its buy rating on Alkermes with a $50 price target on June 22, 2026. Other analysts, like Needham and RBC Capital, also maintained buy ratings with higher targets of $54 and $56, respectively. The consensus among 16 analysts is a buy, with an average target price of $47.19.
About Alkermes plc
Alkermes plc is a biopharmaceutical company based in Dublin, Ireland. It focuses on developing and commercializing drugs for neurological disorders, opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. The company's portfolio includes marketed products like ARISTADA, VIVITROL, and LYBALVI, as well as proprietary technology platforms for third-party collaborations. Founded in 1987, Alkermes employs about 2,050 people under the leadership of CEO Richard F. Pops.
Bottom Line
TD Cowen's reiteration of a buy rating for Alkermes plc suggests continued confidence in the company's growth potential. Investors track these analyst updates for insights into stock performance expectations. It's important to remember that analyst ratings are just one factor in evaluating a stock, and the 13F filings are backward-looking, reflecting past positions.
Get Alkermes plc alerts
New 13F filings, insider trades, and analyst moves on $ALKS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.